Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

Drug Target Review

JANUARY 23, 2024

Cell-based therapies, such as tumour-infiltrating lymphocyte (TIL) therapy, have also drawn significant attention following promising results in a melanoma trial. Such approaches apply artificial intelligence (AI) and machine learning (ML) to predict mutations most likely to be good targets for the immune system.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Broad Institute

MARCH 20, 2024

doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). Networks of cells are critical in mediating immune responses. How do immune cells organize within tumors to effectively eliminate cancer cells? Nature Immunology.

Immune Response 131

Immune Response Hospitals Research Treatment 131

Drug Target Review

JULY 4, 2023

In the realm of immunology, researchers are constantly striving to unlock the intricate secrets of the human immune system. Among the many remarkable components that make up this complex defence network, T cells have emerged as powerful guardians, orchestrating an array of immune responses with great precision.

Immune Response 52

Immune Response Engineering Treatment Therapies 52

Science Daily: Pharmacology News

JULY 12, 2023

Researchers have demonstrated that a transplant surgical procedure (called 'needle trauma') triggers a profound immune response and causes the death of most grafted dopamine neurons. These findings suggest a path for the 'realistic' use of cell therapy to treat neurodegenerative disorders.

Therapies 75

Therapies Immune Response Disease Research 75

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. However, cell-based therapies are intended to leverage those healthy cells via transplant to regenerate damaged tissue.

Therapies 98

Therapies Disease Engineering RNA 98

Drug Target Review

MARCH 1, 2024

Can you elaborate on the key findings of the preclinical data published in Cancer Immunology Research? How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? It may also overcome resistance mechanisms developed by tumours to evade the immune response over time.

Immune Response 105

Immune Response Therapies Vaccine Small Molecule 105

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Plenge Gen

APRIL 7, 2020

Repurposing of approved therapies is the fastest way to impact patients today, as these medicines have regulatory approval to enable investigator-initiated trials and have a manufacturing process to ensure drug supply. (You can download a pdf copy of the blog here.) appeared first on Plenge Gen @rplenge.

Immune Response 52

Immune Response Disease Clinical Trials Drugs 52

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. We are studying the placement of organelles within cells and how they communicate to help better treat disease,” said Coskun. “We

RNA 128

RNA Immune Response Therapies Disease 128

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

Drug Target Review

JANUARY 15, 2024

Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. What aspects prompted this research direction? The preclinical results demonstrated significant immune responses and tumour regression.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Associating immunomodulatory and cytotoxic payloads on the same ADC could also amplify the therapeutic effect of cytotoxic payloads harnessing the power of the immune system to target tumour cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Drug Target Review

OCTOBER 19, 2023

Their research centres around a remarkable immune protein called IL-31, which not only induces itching but also plays a crucial role in regulating inflammation. The question of how the body knows when to stop itching has intrigued researchers for years. The results were both surprising and enlightening.

Immune Response 104

Immune Response Regulations Treatment Therapies 104

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Target Review

OCTOBER 16, 2023

Their close resemblance to the patient and disease state makes PDOs a valuable and scalable source of biological material to interrogate in disease research and drug discovery. This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response.

Disease 122

Disease Immune Response Cell Biology Therapies 122

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Target Review

SEPTEMBER 11, 2023

The solution devised by the Stanford research team involves creating a biomolecule that combines an enzyme-based “scissors” called mucinase (a type of protein-cutting enzyme known as a protease) with a cancer cell -targeting nanobody (a fragment of an antibody).

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

Conversations in Drug Development Trends

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research 52

Research Clinical Trials Therapies Immune Response 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

The Premier Consulting Blog

APRIL 18, 2024

Development of cell and gene therapies is growing rapidly, given the major advances in genomic technologies and increasing scientific understanding of genetic regulation and immunology. This blog will outline three characteristics of a successful nonclinical program to support entry into clinical trials for a cell or gene therapy product.

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. These can include anti-tubulin compounds, potentially reducing side effects and improving quality of life.

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors.

Therapies 52

Therapies Immune Response Research Engineering 52

Alta Sciences

JANUARY 11, 2024

It is estimated that there are over 6,000 monogenic diseases, affecting over 350 million people worldwide; for these diseases, cell and gene therapy may provide hope for a cure. However, there are significant challenges associated with the successful development of these complex, leading-edge therapies. what is the altascientist?

Therapies 52

Therapies Immune Response Disease Virus 52

Drug Target Review

JANUARY 15, 2024

Researchers from the Nara Institute of Science and Technology (NAIST) have used the reverse-blastocyst complementation (rBC) method to understand the conditions required to form lungs in rat-mouse chimeric models. This has warranted more research into the viable conditions required to generate PSC-derived organs. Cell Stem Cell.

Immune Response 113

Immune Response Disease Science Therapies 113

PLOS: DNA Science

FEBRUARY 8, 2024

Borrowed from Bacteria Researchers are using the gene editing tool CRISPR to improve upon naturally-evolved human microbiomes, to build a better probiotic. The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them.

Immune Response 98

Immune Response DNA Engineering Virus 98

The Pharma Data

JANUARY 18, 2021

Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy. Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. gene therapy company (hereafter Neurophth), and AAVnerGene Inc. ,

Therapies 52

Therapies Immune Response DNA Treatment 52

Broad Institute

JULY 26, 2022

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. Study after study had suggested that A.

Research 52

Research Immune Response Medical Schools Disease 52